Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion type Assertion NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_head.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion description "[These preclinical data suggest that ex vivo-exPBNK modified with anti-CD20 CAR may have therapeutic potential for treating patients with poor-risk CD20(+) hematologic malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_provenance.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion evidence source_evidence_literature NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_provenance.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion SIO_000772 25492700 NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_provenance.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion wasDerivedFrom befree-2016 NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_provenance.
- NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_assertion wasGeneratedBy ECO_0000203 NP1246697.RA6XGExUafmOg_UvHTVaSQSlUscY4Zm-xklv7AW557NsI130_provenance.